Objective: to assess the effectiveness of oral trazodone 150 mg/d for treatment of erectile dysfunction. Patients and methods: a double-blind, placebo controlled, multicentre trial. A run-in period of two weeks was followed by four weeks of medication. Evaluation was done by patients diary, a questionnaire and Rigiscan TM nightly penile tumescence and rigidity (NPTR) measurements in the second and sixth week of the trial. Results: 69 patients were randomised, two patients never returned for follow-up, nine patients stopped the medication due to side-effects, so 58 patients are evaluable for effect assessment. Half of the patients suffered psychogenic impotence. There was no signi®cant difference in the subjective results of trazodone compared to placebo. Side effects occurred more often with the use of trazodone, but this was not statistically signi®cant. Conclusion: In a group of patients, that was not selected on the basis of the etiology of the erectile dysfunction, nor selected on the duration of the complaint, the ef®cacy of trazodone 150 mg/d, could not be shown.
Introduction
Oral medication for erectile dysfunction has a rich history. 1 Even today all kinds of herbal and animal matter is sold all over the world to men desiring a better erection. Pharmaca as vitamin E and testosterone have been used, but are not considered rational treatment anymore. Yohimbine is a drug that may improve erections. The alpha adrenoceptor blocking properties make it a rational choice and it has been tested in double blind studies for both organic and psychogenic impotence. 2, 3 Trazodone, an oral drug for treatment of depressions, has an alpha adrenoceptor blocking effect, in combination with a central effect on the serotoninergic system. This combination could increase its ef®cacy for treatment of erectile disorders. 4±6 Trazodone may cause priapism and may increase libido. It has been tested in animals and in vitro on human cavernous tissue. 7, 8 Its ability to induce erections has been shown by injecting it intracavernously in humans. 9 Nocturnal erections are prolonged by trazodone. 8, 10 Of the serotoninergic system especially the 5-HT 1A , 5-HT 1C and the 5-HT 2 receptor subtypes play a facilitatory role in human sexual behavior. 11, 12 In a comparative study on the antiserotinergic agents trazodone, ketanserin and mianserin with placebo, trazodone was the superior drug for treatment of erectile dysfunction. 13 Clinical experience with patients is encouraging. 10, 14, 15 We conducted a multicentre, double-blind study on oral trazodone vs placebo for patients with erectile dysfunction.
Patients and methods
New patients who consulted the urologist for erectile dysfunction were invited to join this study. History taking and physical examination were done, but a more thorough analysis was postponed until the patient had completed the trial, in order to avoid selection bias. The analysis could implicate hormonal evaluation, consultation of a sexuologist, Rigiscan TM realtime assessment of erectile response to visual, sexual stimulation, when negative enhanced by intra-cavernous stimulation, cavernosometry/ graphy, colour doppler assessment or neurophysiologic evaluation as needed.
Patients already on treatment with intracavernous self-injections or with a vacuum device were also invited to join the study, provided they stopped these methods for the duration of the study. Excluded were patients with severe kidney or liver disorders, and patients using anti-hypertensives, psychopharmaca or other drugs that may in¯uence erectile function, especially alpha or beta blocking agents.
Patients were given identical looking capsules containing either 50 mg trazodone or a placebo. Randomisation was performed in six lots, per institute (2 urologic clinics). During six weeks the patients kept a diary with details on sexual function and complains. After two weeks they started using one capsule in the morning and two capsules in the evening, so a daily dose of 150 mg trazodone was tested. At the end of week six the patients were asked their opinion of the treatment. Patients were requested to do Rigiscan TM nocturnal penile tumunesence and rigidity measurements (NPTR) at home, two nights in the second week and two nights in the sixth week of the trial. (Rigiscan device, Dacomed Corp.)
Statistical methods
Main endpoint in the study is the percentage of patients, who indicated that the medication works well. It is supposed that this percentage will be 15% in the placebo group. We are interested in substantial improvement using trazodone treatment, for example 50%. In order to be able to detect such a difference using a 0.05 (one-sided) and power 85%, it can be shown that 2 6 35 70 patients have to be entered. Continuous values (age) between groups were compared with the Mann-Withney Utest. Percentages from 2 6 2 tables and the main endpoint with four categories were compared between groups with a chi-square test. The signi®-cance level used was 0.05.
Results
A total of 69 patients was randomised. Patient characteristics are listed in Table 1 . Of the 32 men using trazodone, 26 were evaluable for effect assessment and of the 37 mean who used placebo, 32 were evaluable. Of the nine patients who were not evaluable, two never returned for a follow-up visit, and seven stopped for reasons of side effects. There was no signi®cant difference in age (P 0.77) between trazodone and placebo users. The patients in the placebo group appeared to have received a signi®cant higher percentage of former treatment (46%) than the patients treated with trazodone (22%) (P 0.04).
In both approximately 47% of the men wished to continue the treatment, although only four of the trazodone users and ®ve of the placebo users considered the drug to be effective, with acceptable side-effects. So the patients wish to continue treatment is not a valid item for treatment ef®cacy.
The evaluation of the treatment by the patients is listed in Table 2 . There was no signi®cant difference in the subjective results between trazodone and placebo (P 0.98). In both groups only approximately 16% of the patients reported that the medication works well. Psychogenic impotence patients did respond favourably more often than the other patients did, 23% vs 15%, (response measured as`works well' or`works, but too many side effects') but the difference was not signi®cant (P 0.45).
In the four weeks of treatment, six patients stopped the trazodone because of side effects, while only three patients in the placebo group did so. The side-effects are listed in Table 3 .
NPTR measurements in the second and the sixth week were performed by 15 patients. A comparison of the results in the second week with the results in the sixth week was done by three authors (WM, RFK and RBF) independently and blinded. The results are listed in Table 4 . In the majority of the 15 patients who completed the four sessions, no changes were found.
Discussion
A placebo has a positive effect in the treatment of erectile dysfunction. This undoubtedly explains the popularity of all sorts of folk remedies. The placebo effect is dependent on the patient's expectance and is probably lower in patients participating in a placebo controlled study with informed consent. Trazodone was considered an effective drug with acceptable side effects by 15% of the patients using it. The numbers are too small for reliable conclusions in subgroups, for example according to etiology of their erectile dysfunction. Considering all 69 patients, we did not ®nd trazodone to be more effective than placebo.
Our attempt to obtain hard data by rigiscan TM NPTR measurements proved to be very demanding on the logistics of the study and on patient compliance. Only 15 patients completed the NPTR measurements and no differences were found between the trazodone users and the placebo users. This is contrary to the results from Saenz de Tejada et al 8 ; possibly this difference is explained by three important factors: ®rstly they investigated healthy volunteers, secondly the mean age in their group was 24 y, and thirdly they measured total tumescence time with mercury strain gauges.
Some authors try to improve the results with trazodone by combining it with other medication in order to pro®t from synergistic effects. The combination of 50 mg trazodone with 15 mg yohimbine has recently been reported effective in a group of patients with nonorganic erectile dysfunction. The responders had suffered impotence for a signi®cant shorter period than the nonresponders (6 vs 18 months). 16 This negative correlation of duration of the complaint and success of treatment was con®rmed in a retrospective analysis by Lance of 182 impotent patients. 15 A positive response was found in 48% of patients who suffered from impotence for less than one year, while only 16% of patients with complaints lasting more than 60 months reported improvement. Since only four of our patients had their complaint less than 6 months and 46 patients had their complaint longer than 18 months, we can draw no conclusions on this matter.
In theory, the best candidates for treatment with trazodone are those patients with performance anxiety or a low libido, who have no physical problems and who have had their erectile dysfunction for less than one year. A study in this speci®c group may still be worthwhile. 
